Pain & Inflammation. Antibe currently has three drug candidates addressing a variety of conditions associated with degenerative disease and inflammation. Our lead candidate, ATB-346 (in Phase 2), is a naproxen derivative that has been shown to deliver pain relief with significantly less gastrointestinal damage than is typically associated with NSAID use.

Regenerative Medicine. Antibe is pursuing both internal development and licensing opportunities to support growth of its regenerative medicine portfolio targeting tissue regeneration in oral and maxillofacial surgery. Typically these products are regulated as medical devices (ie. 510(k) pathway) and can typically obtain regulatory approval within 12 months.

all dollar amounts stated in USD
CANDIDATE TARGET INDICATION PARTNER STATUS MARKET NICHE STATUS
PAIN & INFLAMMATION: Oral Therapeutics
ATB-346 Acute & chronic pain Antibe Osteoarthritis, rheumatoid arthritis, etc. Phase 2
ATB-352 Acute pain Antibe Gout, dental pain, post-surgical pain, etc. Pre-clinical
ATB-340 Anti-thrombotic Antibe Stroke prevention, cancer prevention Pre-clinical
REGENERATIVE MEDICINE: Medical Devices
PentOSTM (CGX-283) Bone regeneration Partnered(1) Oral and maxillofacial surgery Recently approved
CGX-227 Bone regeneration Antibe Oral and maxillofacial surgery Pre-clinical
CGX-443 Bone regeneration Antibe Oral and maxillofacial surgery Pre-clinical
URISTTM (CGX-276) Bone regeneration Partnered(2) Oral and maxillofacial surgery Clinical development
1) Antibe licensed the global distribution rights for PentOSTM for oral & maxillofacial surgery. 2) Antibe licensed the exclusive Canadian distribution rights for URISTTM for oral & maxillofacial surgery from Induce Biologics in Jan/16.